Fundamental Analysis of WEREWOLF THERAPEUTICS INC(NASDAQ:HOWL) stock

Fundamental Rating

Overall HOWL gets a fundamental rating of 2 out of 10. We evaluated HOWL against 586 industry peers in the Biotechnology industry. Both the profitability and financial health of HOWL have multiple concerns. HOWL has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HOWL has reported negative net income.

HOWL had a negative operating cash flow in the past year.

In the past 5 years HOWL always reported negative net income.

HOWL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

HOWL's Return On Assets of -23.42% is fine compared to the rest of the industry. HOWL outperforms 77.09% of its industry peers.

Looking at the Return On Equity, with a value of -35.37%, HOWL is in the better half of the industry, outperforming 75.56% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-23.42%
ROE	-35.37%
ROIC	N/A

ROA(3y)-55.86%

ROA(5y)-56.17%

ROE(3y)-69.9%

ROE(5y)-85.47%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

HOWL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HOWL does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for HOWL has been increased compared to 1 year ago.

HOWL has a worse debt/assets ratio than last year.

2.2 Solvency

HOWL has an Altman-Z score of -0.73. This is a bad value and indicates that HOWL is not financially healthy and even has some risk of bankruptcy.

HOWL has a Altman-Z score (-0.73) which is in line with its industry peers.

HOWL has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.

HOWL has a Debt to Equity ratio of 0.24. This is in the lower half of the industry: HOWL underperforms 69.57% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Altman-Z	-0.73

ROIC/WACCN/A

WACC9.17%

2.3 Liquidity

HOWL has a Current Ratio of 6.71. This indicates that HOWL is financially healthy and has no problem in meeting its short term obligations.

HOWL has a better Current ratio (6.71) than 64.62% of its industry peers.

A Quick Ratio of 6.71 indicates that HOWL has no problem at all paying its short term obligations.

HOWL's Quick ratio of 6.71 is fine compared to the rest of the industry. HOWL outperforms 64.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.71
Quick Ratio	6.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HOWL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.34%, which is quite impressive.

The Revenue for HOWL has decreased by -22.23% in the past year. This is quite bad

EPS 1Y (TTM)34.34%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-14.71%

Revenue 1Y (TTM)-22.23%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-83.38%

3.2 Future

The Earnings Per Share is expected to decrease by -8.07% on average over the next years.

HOWL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.

EPS Next Y-29.13%

EPS Next 2Y-10.44%

EPS Next 3Y-9.71%

EPS Next 5Y-8.07%

Revenue Next Year-71.39%

Revenue Next 2Y-12.87%

Revenue Next 3Y-6.49%

Revenue Next 5Y19.24%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HOWL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HOWL. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

HOWL's earnings are expected to decrease with -9.71% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.44%

EPS Next 3Y-9.71%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

HOWL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (5/17/2024, 7:04:24 PM)

4.72

-0.16 (-3.28%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap204.61M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-23.42%
ROE	-35.37%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.09

Health

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.71
Quick Ratio	6.71
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)34.34%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-29.13%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-22.23%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

WEREWOLF THERAPEUTICS INC (HOWL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens